HilleVax, Inc. (NASDAQ:HLVX) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC trimmed its holdings in shares of HilleVax, Inc. (NASDAQ:HLVX) by 11.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 627,669 shares of the company’s stock after selling 80,362 shares during the period. Geode Capital Management LLC’s holdings in HilleVax were worth $1,105,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Maven Securities LTD purchased a new position in HilleVax in the second quarter worth $217,000. BML Capital Management LLC acquired a new position in shares of HilleVax during the 3rd quarter worth $35,000. Algert Global LLC purchased a new position in shares of HilleVax in the 2nd quarter valued at about $519,000. Barclays PLC lifted its stake in shares of HilleVax by 255.6% in the third quarter. Barclays PLC now owns 42,033 shares of the company’s stock valued at $74,000 after purchasing an additional 30,213 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of HilleVax by 27.0% in the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after purchasing an additional 9,073 shares during the period. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Trading Down 2.3 %

Shares of HLVX opened at $2.09 on Friday. HilleVax, Inc. has a twelve month low of $1.55 and a twelve month high of $20.22. The firm has a market capitalization of $104.09 million, a P/E ratio of -0.67 and a beta of 0.75. The firm’s 50-day moving average is $1.94 and its two-hundred day moving average is $2.68.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). Analysts predict that HilleVax, Inc. will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.